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Abstract: The aim of this study was to assess the impact of the 2019 published European Society of Cardi-
ology (ESC)/European Atherosclerosis Society (EAS) guideline on cardiovascular (CV) risk management
compared with its predecessor from 2016 in a cohort in general practice. We performed a cross-sectional
retrospective study with data from electronic medical records. The study cohort included 103,351 patients
with known CV risk. We assessed changes in CV risk classification and low-density lipoprotein cholesterol
(LDL-C) target values, the impact on LDL-C achievement rates, and the current lipid-lowering treat-
ments. Under the 2019 ESC guideline, CV risk categories changed in 27.5% of patients, LDL-C target
levels decreased in 71.4% of patients, and LDL-C target achievement rate dropped from 31.1% to 16.5%.
Among non-achievers according to the 2019 guideline, 52.2% lacked lipid-lowering drugs entirely, and
41.5% had conventional drugs at a submaximal intensity. Of patients in the high-risk and very high-risk
categories, at least 5% failed to achieve the LDL-C target level despite treatment at maximal intensity
with conventional lipid-lowering drugs, making them eligible for PCSK-9 inhibitors. In conclusion, the
2019 ESC/EAS guideline lowered LDL-C target values for the majority of patients in general practice
and halved LDL-C target achievement rates. There is still a large undeveloped potential to lower CV risk
by introducing conventional lipid-lowering drugs, particularly in patients at high or very high CV risk.
A substantial proportion of the patients can only achieve their LDL-C targets using PCSK-9 inhibitors,
which would currently require an at least 10-fold increase in prescribing of these drugs.
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Abstract: The aim of this study was to assess the impact of the 2019 published European Society of 
Cardiology (ESC)/European Atherosclerosis Society (EAS) guideline on cardiovascular (CV) risk 
management compared with its predecessor from 2016 in a cohort in general practice. We 
performed a cross-sectional retrospective study with data from electronic medical records. The 
study cohort included 103,351 patients with known CV risk. We assessed changes in CV risk 
classification and low-density lipoprotein cholesterol (LDL-C) target values, the impact on LDL-C 
achievement rates, and the current lipid-lowering treatments. Under the 2019 ESC guideline, CV 
risk categories changed in 27.5% of patients, LDL-C target levels decreased in 71.4% of patients, and 
LDL-C target achievement rate dropped from 31.1% to 16.5%. Among non-achievers according to 
the 2019 guideline, 52.2% lacked lipid-lowering drugs entirely, and 41.5% had conventional drugs 
at a submaximal intensity. Of patients in the high-risk and very high-risk categories, at least 5% 
failed to achieve the LDL-C target level despite treatment at maximal intensity with conventional 
lipid-lowering drugs, making them eligible for PCSK-9 inhibitors. In conclusion, the 2019 ESC/EAS 
guideline lowered LDL-C target values for the majority of patients in general practice and halved 
LDL-C target achievement rates. There is still a large undeveloped potential to lower CV risk by 
introducing conventional lipid-lowering drugs, particularly in patients at high or very high CV risk. 
A substantial proportion of the patients can only achieve their LDL-C targets using PCSK-9 
inhibitors, which would currently require an at least 10-fold increase in prescribing of these drugs. 
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1. Introduction 
Cardiovascular (CV) disease is the leading cause of death in Europe, accounting for 45% of all 
deaths [1]. Multiple risk factors contribute to CV disease [2], and many are preventable or treatable, 
including hypertension or elevated levels of low-density lipoprotein cholesterol (LDL-C) [3]. 
Individual risk factors are of variable importance and their individual contribution to overall CV risk 
is complex. Risk stratification schemes are widely used to reduce complexity in risk estimation for 
individual patients. They typically include morbidities such as hypertension or diabetes mellitus 
(DM) and laboratory values such as total cholesterol [2]. 
In Europe, the most widely used risk classification scheme is the one proposed by the European 
Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). It divides patients into 
four risk categories ranging from “low risk” to “very high risk” [4,5]. To lower CV risk, the ESC/EAS 
specifies LDL-C target values for each risk category and, where required, recommends 
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pharmacological treatment to achieve those target values. In August 2019, a major update of the 
ESC/EAS guideline for the management of dyslipidemia was published, with changes to the CV risk 
classification scheme and LDL-C target values [4]. The revised CV risk classification scheme includes 
adaptations to the way morbidities and laboratory values are accounted for. Furthermore, LDL-C 
target values were lowered for most risk categories. The 2019 update on the ESC/EAS guideline is 
substantial, and it necessitates risk classification as well as LDL-C target value to be updated in 
certain patients. Given its complex nature and the interplay of factors relevant to risk classification, 
the proportion of patients actually requiring a change in risk classification and LDL-C target value in 
general practice is uncertain. Furthermore, it is unclear how the proportions of patients achieving 
LDL-C target values will change compared to the 2016 guideline, and what the related therapeutic 
implications are for patients in real-life general practice. 
Therefore, the aim of this study was to assess the impact of the 2019 ESC/EAS guidelines on CV 
risk management in a cohort of patients in real-life general practice. The specific objectives of this 
study were to evaluate (1) the proportions of patients for whom the 2019 ESC/EAS guideline entailed 
changes in CV risk classification and LDL-C target values, together with the directions (increase or 
decrease) and reasons for reclassification. (2) The impact on LDL-C target achievement rates for each 
CV risk category. (3) Current lipid-lowering treatments (in terms of dosage and drug combinations) 
of patients with available LDL-C measurements but failing to achieve the 2019 target levels, stratified 
by 2019 CV risk category. 
2. Methods 
2.1. Study Design, Setting, and Participants 
We performed a cross-sectional retrospective analysis using data from the family medicine 
international classification of primary care (ICPC) research using electronic medical records (FIRE) 
project [6]. As of August 2019, more than 540 participating Swiss general practitioners (GPs), i.e., 
10.5% of GPs working in the German-speaking region of Switzerland [7], provided anonymized 
patient and routine data from their electronic medical records to the FIRE database. We included all 
patients with at least one consultation in the study observation period starting 1 September 2016 
(publication of the 2016 ESC guideline), and ending 31 August 2019 (publication of the 2019 ESC/EAS 
guideline) (Figure 1). Patients were eligible if available data allowed for CV risk classification 
according to the 2016 or 2019 ESC/EAS guideline (see below). The local Ethics Committee of the 
Canton of Zurich waived approval, because the FIRE project was considered outside the scope of the 
Federal Act on Research involving Human Beings (BASEC-Nr. Req-2017-00797). 
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Figure 1. Flowchart of study protocol. GPs: general practitioners; ESC: European Society of 
Cardiology; LDL-C: low-density lipoprotein cholesterol. 
2.2. Implementation of CV Risk Classification 
Both the 2016 and 2019 ESC/EAS guidelines combine two different assessments to define the CV 
risk categories, the first of which being the “Systematic COronary Risk Estimation” (SCORE) [8], and 
the second reflecting the presence of specific morbidities and risk factors. Here we provide an 
overview of the classification process, which was implemented within the FIRE database to assess 
the CV risk categories for each patient according to the 2016 and 2019 ESC/EAS guidelines (see 
Supplementary Material 1 for the fully detailed description of the classification process). 
Risk assessment using the SCORE directly provides prognostic probabilities for fatal CV events 
based on gender, age (40–70 years), smoking status, parametric values of systolic blood pressure (120–
180 mmHg) and total cholesterol (4–8 mmol/L) in untreated patients without CV disease. We 
calculated SCORE probabilities according to the guidelines’ instructions for low-risk countries. We 
used the most recent untreated total cholesterol and systolic blood pressure values if they were 
concurrently available within 5 years as CV risk progression is considered to be small during the 
length of this period [9]. 
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The risk assessment based on morbidity and risk factors encompasses established CV disease, 
DM with target organ damage, DM with major risk factors (advanced age, smoker, dyslipidemia, 
hypertension, and obesity) [10], severe or moderate chronic kidney disease (CKD), markedly elevated 
single risk factors, and DM without risk factors/target damage. We identified the above using ICPC-
2 codes [11], laboratory values, vital signs, or anatomical therapeutic chemical [12] codes for 
medication exclusively indicated for the abovementioned morbidities depending on availability. No 
age restrictions were applied. 
We combined the SCORE and the risk classifications based on morbidity to generate the 
composite ESC/EAS risk classification. Whenever multiple reasons for classification were available at 
the same time, the one with the higher CV risk was adopted. A detailed analysis highlighting 
differences between the 2016 and 2019 ESC/EAS guidelines is provided in the Supplementary 
Material 1. 
2.3. Database Query and Variables 
From the FIRE database, we extracted the following patient data: gender; year of birth; most 
recent CV risk category within 10 years according to both the 2016 and 2019 ESC/EAS guidelines as 
described above; reasons for classification according to the 2016 and 2019 ESC/EAS guidelines, 
respectively (specific morbidity or SCORE); value of the last available LDL-C measure in the 
observation period after the last CV risk assessment; information (product, daily dose) about lipid-
lowering drugs (statins, ezetimibe, proprotein convertase subtilisin/kexin-9 (PCSK-9) inhibitors, and 
their combinations). The intensity of statin treatment was inferred from drug name and daily dose 
according to the classification in the 2014 American College of Cardiology and American Heart 
Association guidelines [13]. 
2.4. Data Analysis 
LDL-C target values were adopted as reported in the ESC/EAS guidelines. In 2016, target values 
were <3.0 mmol/L for low/moderate risk, <2.6 mmol/L for high risk, and <1.8 mmol/L for very high 
risk; in 2019 target values were <3.0 mmol/L for low risk, <2.6 mmol/L for moderate risk, <1.8 mmol/L 
for high risk, and <1.4 mmol/L for very high risk. 
We carried out all analyses using the statistical software package R (Version 3.5.0) [14]. We used 
counts and proportions (n and %) as well as medians with interquartile ranges (IQR) to describe the 
data. 
3. Results 
3.1. Characteristics of Patients 
We assessed half a million patients in general practice and identified 103,351 with known CV 
risk and thus eligible for this study (Figure 1). The patients’ median age at the end of the observation 
period was 64 years (IQR = 53–76), and 49.2% (n = 50,884) were female. LDL-C could be followed up 
in 23.6% (n = 24,356) of patients after their CV risk was determined. The distribution across the four 
risk categories according to the 2016 ESC guideline was as follows: low risk, 9.6%; moderate risk, 
21.4%; high risk, 29.5%; and very high risk, 39.6%. Based on the 2019 ESC/EAS guideline, the 
distribution was as follows: low risk, 9.8%; moderate risk, 17.0%; high risk, 53.1%; and very high risk, 
20.1%. In the low- and moderate-risk categories, all patients were identified via their SCORE values 
whereas in the high- and very high-risk categories, only a minor percentage was identified by SCORE 
values (high-risk category 2016: 6.3%, 2019: 8.2%; very high-risk category 2016: 0.2%, 2019: 6.3%). 
Detailed patient characteristics stratified by guideline and risk category are presented in Table 1. 
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Table 1. Patient characteristics stratified according to ESC/European Atherosclerosis Society (EAS) 
guideline and cardiovascular (CV) risk category (total number of patients in 2016: 98,932; total number 
of patients in 2019: 103,351). 
2016 Guideline 
Patient Characteristics 
Low Risk Moderate Risk High Risk Very High Risk 
(n = 9461) (n = 21,138) (n = 29,176) (n = 39,157) 
Median age (IQR) 47 (44–51) 58 (53–63) 69 (53–81) 72 (61–81) 
% female  75.7 38.6 57.0 42.6 
% with an LDL-C measurement 9.9 16.1 19.1 36.9 
median LDL-C (IQR) mmol/L 3.1 (2.5–3.8) 3.3 (2.7–4) 3.0 (2.3–3.9) 2.3 (1.8–3.1) 
Morbidities 
s % with previous CVD 0.0 0.0 0.0 27.8 
% with severe CKD 0.0 0.0 0.0 10.2 
% with moderate CKD 0.0 0.0 57.9 25.1 
% with diabetes 0.0 0.0 23.6 74.2 
% with dyslipidemia 53.5 68.7 32.5 39.8 
% with hypertension 11.7 22.3 43.4 67.2 
% with obesity 15.7 16.3 12.5 25.5 
Lipid-lowering drugs 
% no treatment 97.6 93.3 80.0 52.2 
% statin only 2.1 6.0 18.3 42.7 
% statin and ezetimibe  0.18 0.46 1.37 4.52 
% ezetimibe only 0.11 0.19 0.33 0.49 
% statin and PCSK-9 inhibitors 0.00 0.00 0.03 0.06 
% PCSK-9 inhibitors only 0.00 0.00 0.01 0.02 
2019 Guideline 
Patient Characteristics  
Low Risk Moderate Risk High Risk Very High Risk 
(n = 10,094) (n = 17,583) (n = 54,876) (n = 20,798) 
Median age (IQR) 48 (44–52) 58 (53–62) 68 (56–78) 74 (66–83) 
% female  74.8 38.9 51.8 38.7 
% with an LDL-C measurement 9.0 13.5 24.6 37.9 
median LDL-C (IQR) mmol/L 3.1 (2.5–3.6) 3.2 (2.6–3.8) 2.9 (2.1–3.7) 2.2 (1.7–3) 
Morbidities 
% with previous CVD 0.0 0.0 0.0 52.4 
% with severe CKD 0.0 0.0 0.0 19.1 
% with moderate CKD 0.0 0.0 36.8 31.5 
% with diabetes 0.0 0.0 47.9 46.4 
% with dyslipidemia 52.2 67.0 38.5 48.1 
% with hypertension 10.8 22.7 45.4 78.6 
% with obesity 14.9 16.9 15.4 29.8 
Lipid-lowering drugs  
% no treatment 98.0 94.2 74.6 42.2 
% statin only 1.8 5.3 23.4 50.5 
% statin and ezetimibe  0.11 0.39 1.61 6.63 
% ezetimibe only 0.09 0.15 0.38 0.60 
% statin and PCSK-9 inhibitors 0.00 0.00 0.02 0.12 
% PCSK-9 inhibitors only 0.00 0.01 0.01 0.04 
IQR: interquartile range; LDL-C: low-density lipoprotein cholesterol; CVD: cardiovascular disease; 
CKD: chronic kidney disease; PCSK-9: proprotein convertase subtilisin/kexin-9. 
3.2. Impact of Guideline Update on Risk Classification and LDL-C Target Values 
The 2019 ESC/EAS guideline caused a change in CV risk classification in 27.5% (n = 28,419) of 
patients. Specifically, the risk category decreased in 19.8% (n = 20,493) and increased in 3.4% (n = 
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3507). In addition, 4.3% (n = 4419) were newly classified (i.e., without classification under the criteria 
of the 2016 ESC guideline). The reasons for risk category reclassification or new classification were 
modifications to the identification scheme for DM with major risk factors (18.8%, n = 19,422), SCORE 
adaptations (5.2%, n = 5354), and adaptation in the identification scheme of markedly elevated single 
risk factors (3.5%, n = 3643). The changes to the identification scheme for DM with major risk factors 
led to downgrading risk in patients with DM with only one or two major risk factors from the very 
high- to the high-risk category. For a detailed visualization of the reasons for risk categories 
reclassification, see the Supplementary Material 1, Figure S1. 
LDL-C target values changed in 71.4% (n = 73,781) of patients. All changes to LDL-C targets 
resulted in lower LDL-C target values. The impact of the 2019 ESC/EAS guideline on risk 
classification and LDL-C target levels is shown in Figure 2. The median LDL-C distance to target level 
increased in the moderate-risk category by a factor of 2 (2016: 0.3 (0–1.0) mmol/L; 2019: 0.6 (0–1.2) 
mmol/L), in the high-risk category by a factor of 2.8 (2016: 0.4 (0–1.3) mmol/L; 2019: 1.1 (0.3–1.9) 
mmol/L), and in the very high-risk category by a factor of 1.6 (2016: 0.5 (0–1.3) mmol/L; 2019: 0.8 (0.3–
1.6) mmol/L). No changes in LDL-C target values were introduced in the low-risk category. 
 
Figure 2. Impact of the 2019 ESC/EAS guideline on CV risk classification and LDL-C target values. 
Flows represent patients’ classification according to the 2016 and 2019 guidelines; the size of each 
flow is in proportion to the number of patients. Colors indicate changes in LDL-C target values: red: 
decrease of LDL-C target value, grey: no change of LDL-C target value. * no classification. 
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3.3. Impact of Guideline Update on LDL-C Target Value Achievement 
A follow-up LDL-C value needed to assess target achievement was available in 24.6% (n = 24,356) 
of patients classified according to the 2016 ESC guideline and in 23.9% (n = 24,670) of patients 
classified according to the 2019 ESC/EAS guideline. In total, 31.1% (n = 7582) of patients achieved the 
recommended LDL-C target value according to the 2016 ESC guideline, and 16.5% (n = 4066) 
according to the 2019 ESC/EAS guideline. Figure 3 shows the 2016 and 2019 target achievement rates 
stratified by risk category. 
 
Figure 3. LDL-C target achievement stratified by guideline and risk category. 
3.4. Lipid-Lowering Treatment in LDL-C Target Non-Achievers 
Of the patients not achieving LDL-C target values recommended by the 2019 ESC/EAS guideline 
(n = 20,604), 52.2% (n = 10,748) received no lipid-lowering drugs at all, 41.5% (n = 8550) were treated 
with statins only, 5.5% (n = 1139) received a combination of statins and ezetimibe, and 0.11% (n = 22) 
received a statin and a PCSK-9 inhibitor. Of the patients treated with statins, 38.5% (n = 3730) received 
a high-intensity treatment. Detailed numbers stratified by risk category are given in Table 2. 
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Table 2. Characteristics of patients not achieving LDL-C target values according to the 2019 ESC/EAS 
guideline (total number of patients = 20,604). 
2019 
Patient Characteristics 
Low Risk Moderate Risk High Risk Very High Risk 
(n = 475) (n = 1769) (n = 11,551) (n = 6809) 
Median age (IQR) 49 (45–53) 59 (55–63) 67 (57–76) 72 (64–79) 
% female  81.3 41.0 51.5 35.5 
median LDL-C (IQR) in 
mmol/L 
3.6 (3.3–4.0) 3.5 (3.1–4.0) 3.1 (2.5–3.9) 2.4 (1.9–3.2) 
Median distance to LDL-C 
target (IQR) in mmol/L 
0.6 (0.3–1.0) 0.9 (0.5–1.4) 1.3 (0.7–2.1) 1.0 (0.5–1.8) 
Lipid-lowering drugs 
% no treatment 93.3 89.1 58.5 28.9 
% statin only 5.3 10.1 37.7 58.7 
% statin and ezetimibe  0.84 0.45 3.05 11.4 
% ezetimibe only 0.63 0.40 0.74 0.84 
% statin and PCSK-9 
inhibitors 
0.00 0.00 0.06 0.22 
% PCSK-9 inhibitors only 0.00 0.00 0.02 0.07 
Statin treatment intensity 
% high 1.5 2.3 12.0 33.8 
% moderate 2.9 6.9 23.7 29.9 
% low 0.2 0.5 1.7 2.1 
% missing 1.5 0.9 3.3 4.4 
IQR: interquartile range; LDL-C: low-density lipoprotein cholesterol; PCSK-9: proprotein convertase 
subtilisin/kexin-9. 
4. Discussion 
In this study, we assessed the impact of the new 2019 ESC/EAS guideline on CV risk 
management in a cohort in general practice with known CV risk. The new guideline’s impact was 
extensive and lowered LDL-C target values for 71% of the patients. In the most relevant group of 
patients in the high-risk and very high-risk categories, only 15% of patients currently achieve their 
respective LDL-C target values according to the 2019 guideline, suggesting that intensified treatment 
is needed. While in most of these patients, conventional lipid-lowering drug treatment can either be 
initiated or intensified, in at least 5%, the conventional treatment methods are exhausted and PCSK-
9 inhibitors are recommended. In practice, this would translate into an over 10-fold increase in the 
prescription of PCSK-9 inhibitors. 
With respect to its predecessor from 2016, changes in the 2019 ESC/EAS guideline comprised 
updated classification criteria and new LDL-C target values for CV risk categories. When applied to 
our real-life general practice cohort, we noted few changes in classification criteria for low-risk and 
moderate-risk categories, but every second patient in the former very high-risk category was 
downgraded into the high-risk category. Thereby, the guideline change caused a net downgrading 
in CV risk. However, it is important to understand that by also lowering the LDL-C target levels 
across all but the low-risk category, the new guideline actually tightened the recommendations for 
71% of all patients. For clinicians, the identification of patients with changed LDL-C target levels is 
straightforward: LDL-C target levels changed for everyone except for patients with DM and less than 
three additional CV risk factors, and for those in the low-risk category. 
By tightening treatment goals, the new 2019 ESC/EAS guideline increased the proportion of 
patients not meeting their LDL-C targets. In patients in the high-risk and very high-risk categories, 
the LDL-C target achievement rate halved, from 30% to 15%. This population may be the most 
relevant to consider, since evidence of the effectiveness of lipid-lowering drugs is weaker in low-risk 
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and moderate-risk patients [15,16]. With respect to the current treatment of the patients who are not 
achieving their LDL-C target values, we found that half the patients still used no lipid-lowering drugs 
at all. The largest undeveloped potential to reach LDL-C target values therefore lies in initiating lipid-
lowering treatment in the first place. This finding, surprising as it may seem, is in line with study 
results covering several other major European healthcare systems [17–19]. The second largest 
potential lies with the 45% of patients receiving conventional lipid-lowering drug treatment at 
submaximal intensity. Side effects, however, might limit maximizing the intensity of treatment in 
several of these cases [20]. At least 5% of the patients categorized as high-risk or very high-risk receive 
maximum lipid-lowering treatment already, and could further approximate their LDL-C target 
values only by introducing a PCSK-9 inhibitor. The true proportion benefitting from PCSK-9 
inhibitors might be even higher as we were unable to account for statin intolerance. Within our cohort 
in general practice, the current prescription rate for PCSK-9 inhibitors is 0.37% and it would thus 
need to increase more than 10-fold to achieve LDL-C targets in these patients at high or very high CV 
risk. Given the current prices of PCSK-9 inhibitors and the small additional benefits in terms of 
absolute risk reductions, the implementation of such a recommendation may be contested from a 
cost-efficiency perspective [21–23]. 
Economic barriers may however not be the bottleneck to overcome in order to fully adopt the 
current guideline in general practice. Implementation of clinical practice guidelines is often slow in 
general practice, and guidelines on CV risk reduction are no exception [24–26]. Since 1987, guidelines 
on CV risk reduction have gradually increased the proportion of patients eligible for lipid-lowering 
drugs [27], and the current 2019 ESC/EAS guideline continues this trend. In general practice, such 
changes often encounter disagreement and lack of applicability for various reasons [28]. Given these 
multiple barriers in the health care chain, coordinated national strategies may be required to tailor 
and successfully implement recommended changes in CV risk management [29]. 
Strength and Limitations 
To our knowledge, this is the first study assessing the real-life impact of the new 2019 ESC/EAS 
guideline on CV risk management. Our study encompassed over 100,000 individual patients from a 
general practice cohort, and is therefore highly representative of the large population to which the 
new guideline applies. 
The major limitation of this study is its inherent risk of selection bias on different levels. Selection 
bias on the GP level might occur since participation in the FIRE project is voluntary and requires the 
use of electronic medical records which is not standard in Switzerland [30]. Therefore, GPs 
contributing to the FIRE database might represent a higher performing sample of GPs. However, age 
and gender structure of GPs participating in the FIRE project is similar to census data published by 
the Swiss medical association [31]. Furthermore, there is a risk for information bias: failure to enter 
data creates a risk of under-estimating CV risk categories and current drug treatments, or might even 
prevent assessing CV risk categories at all. CV risk categories may therefore be systematically under-
estimated, and our results should be understood as minimal estimates. Laboratory values, however, 
are automatically fed into the database; therefore, our results regarding LDL-C target achievement 
are likely robust. However, it is still likely that the selection of patients with available LDL-C 
measurements entailed a certain risk of bias, as these patients might be more closely managed due to 
their higher needs. Additionally, it should be noted that the medication information stems from 
prescriptions, and information on patient compliance was not available. Regarding ESC/EAS 
guideline implementation, we noted that the guidelines leave room for interpretation. For example, 
there is some ambiguity in assigning SCORE values for certain parameter ranges (age, LDL-C and 
blood pressure). This required us to make more precise definitions than actually stated in the 
guideline. Additionally, we extended age categories for the 2016 ESC guideline to range from 65 to 
67 to achieve comparability with the 2019 ESC/EAS guideline. Thus, the results reflect, to a small 
degree, our own interpretation of the guidelines, but the same room for interpretations is also left to 
GPs when applying it. Lastly, our definition of LDL-C target level achievement rests exclusively on 
reaching the respective thresholds, whereas a 50% reduction in LDL-C also qualifies as target 
J. Clin. Med. 2020, 9, 2140 10 of 12 
 
achievement according to the guidelines. We were unable to determine this measure because pre-
treatment LDL-C values were only available for a minority of patients. Such electronic medical 
record-specific limitations, however, are not a relevant limitation to reliability in predicting CV risk, 
according to Wolfson et al. [32]. 
5. Conclusions 
In conclusion, the impact of the 2019 update of the ESC/EAS guideline for the management of 
dyslipidemia is substantial, lowering the LDL-C target values for 71% of patients with known CV 
risk in general practice. Achievement rates of LDL-C targets were halved and increased the 
proportions of patients eligible for intensified lipid-lowering treatment. While in most cases initiating 
or increasing intensity of conventional lipid-lowering treatment is recommended, at least 5% of 
patients are eligible for PCSK-9 inhibitors, which would lead to a 10-fold increase of prescriptions for 
these drugs. 
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